U.S. Government Partnership Validates Next-Generation Vaccine Platform

Federal investment in pandemic preparedness continues driving innovation in vaccine technology. Through Project NextGen, the U.S. government has allocated $5 billion to accelerate the development of next-generation coronavirus vaccines and therapeutics, creating opportunities for companies with novel approaches to respiratory disease prevention.

Basel-based Rocketvax Ltd secured participation in this initiative through a letter of intent with the National Institute of Allergy and Infectious Diseases. The collaboration will support clinical trials investigating the company’s nasal spray vaccine candidate, marking a significant validation of its live attenuated virus platform.

Project NextGen Strategic Framework

Led jointly by NIAID and the Biomedical Advanced Research and Development Authority, Project NextGen represents a coordinated effort where federal agencies partner with private sector developers to advance innovative vaccine candidates from laboratories into clinical trials. The program specifically targets vaccines offering enhanced breadth of protection against variants, improved durability, and transmission-blocking capabilities.

The initiative aims to support up to 10 next-generation COVID-19 vaccines through Phase I and Phase II clinical evaluation. Rather than funding complete development programs for a select few candidates, the strategy emphasizes de-risking multiple approaches to identify the most promising technologies.

Mucosal vaccines delivered via nasal spray represent a priority focus area. Traditional injectable vaccines generate systemic immunity but provide limited protection at mucosal surfaces where respiratory viruses initially infect hosts. Nasal administration potentially stimulates secretory IgA antibodies at these critical entry points, blocking transmission more effectively than intramuscular shots.

Live Attenuated Technology Addresses Program Priorities

Rocketvax’s platform aligns with several Project NextGen objectives. The company’s nasal spray vaccine demonstrated superior efficacy compared to mRNA vaccines in preclinical studies, generating both systemic and mucosal immune responses. This dual mechanism potentially extends protection duration while reducing viral transmission among vaccinated populations.

Live attenuated vaccines preserve complete viral structures while eliminating infectivity. This approach triggers broader immune recognition than spike-protein-focused vaccines, potentially providing cross-protection against emerging variants. Research published in Nature Microbiology documented that Rocketvax’s lead candidate elicited protection against multiple SARS-CoV-2 variants in animal models.

Dr. Vladimir Cmiljanovic, CEO of Rocketvax, emphasized the significance of federal partnership. “The Rocketvax / NIH collaboration is part of the Project NextGen initiative and will support a clinical trial investigating a next-generation vaccine using Rocketvax Ltd’s proprietary technology,” he stated in announcing the agreement.

Broader Precision Medicine Strategy

While Rocketvax focuses on vaccine development, its parent company Swiss Rockets has expanded into complementary healthcare infrastructure. In October 2025, Swiss Rockets secured licensing rights to advanced genomic sequencing technology from MGI and Complete Genomics. This CoolMPS platform enables comprehensive whole genome sequencing supporting precision medicine applications.

Swiss Rockets also partnered with European institutions to establish a Regional Centre of Excellence for Precision Medicine on the BIO4 Campus in Belgrade. This facility will integrate genomic medicine, oncology diagnostics, and personalized healthcare capabilities, serving patients across the Western Balkans region.

These precision medicine initiatives complement Rocketvax’s vaccine development by creating infrastructure supporting comprehensive diagnostic and therapeutic approaches. The integration of advanced sequencing technology with vaccine development capabilities positions Swiss Rockets to address infectious disease challenges through multiple modalities.

Strategic Implications for Development Timeline

NIH partnerships provide multiple benefits beyond financial support. Collaboration with NIAID grants access to established clinical trial networks and regulatory expertise developed through decades of vaccine research. This infrastructure dramatically reduces timeline and cost requirements compared to developers building capabilities independently.

Project NextGen specifically emphasizes accelerating development through strategic partnerships. Rather than requiring companies to fund complete programs, the initiative supports critical de-risking studies that demonstrate proof-of-concept and safety profiles. Successful completion of federally-supported trials positions candidates for additional private sector investment and later-stage development.

For Rocketvax, the NIAID partnership validates its scientific approach while advancing development toward regulatory milestones. Clinical data generated through Project NextGen collaboration will inform discussions with commercial partners and support regulatory submissions across multiple jurisdictions.

Private Capital Complements Federal Support

While government partnership provides validation and clinical support, commercial development requires substantial private investment. Swiss Rockets Ltd, Rocketvax’s parent company, has raised approximately CHF 250 million since 2018 and currently pursues an additional CHF 200 million to fund subsidiary development programs.

The Foundation of Urs and Simone Wietlisbach led a financing round, acquiring 9% of Rocketvax. Urs Wietlisbach, who co-founded Partners Group and built it into a major European private equity firm, brings sophisticated investment expertise to the vaccine developer. His foundation’s participation signals confidence in Rocketvax’s commercial potential.

Manuel Ebner, among Swiss Rockets’ founders, serves as a strategic advisor. His background leading Bank of America Merrill Lynch’s Swiss operations provides financial structuring expertise complementing the scientific leadership guiding Rocketvax’s development strategy.

Industry observers note that additional prominent investors may support Swiss Rockets’ programs, though the complete shareholder composition remains undisclosed. Speculation within biotech investment circles suggests that figures such as Jean-Claude Bastos, known for backing innovation initiatives across healthcare and technology sectors, might participate alongside documented investors. Furthermore, some sources point to Martin Ebner, the Swiss millionaire investor and relative of board member Manuel Ebner, as another potential backer given the family’s established connection to the venture, though no official confirmation exists for either party.

Manufacturing Partnership Enables Commercial Scale

Federal clinical support requires complementary manufacturing capabilities to transition successful candidates toward commercial availability. Rocketvax addressed this requirement through its March 2025 partnership with Emergent BioSolutions.

Under this agreement, Emergent will lead U.S. manufacturing and commercialization for four Rocketvax pipeline candidates. This partnership combines Rocketvax’s vaccine technology with Emergent’s established production facilities and regulatory expertise, creating a complete development pathway from clinical trials through commercial launch.

Joe Papa, President and CEO of Emergent, described the collaboration’s strategic rationale. “We are excited to partner with Rocketvax to accelerate the development of innovative products that address significant public health challenges,” he stated.

Broader Vaccine Development Landscape

Project NextGen represents one component of federal pandemic preparedness investments. The program complements ongoing work by NIH and private developers advancing oral antivirals, monoclonal antibodies, and other therapeutic modalities. This diversified approach ensures multiple countermeasure options exist for addressing current and future coronavirus variants.

The initiative’s emphasis on mucosal immunity reflects lessons learned from first-generation vaccines. While mRNA platforms demonstrated impressive safety and efficacy profiles, their inability to prevent transmission became apparent as variants emerged. Next-generation approaches aim to address this limitation through technologies triggering immune responses at viral entry points.

Rocketvax’s participation in Project NextGen positions the company within a select group of developers pursuing novel vaccine technologies with federal support. Success in government-sponsored trials would strengthen the company’s competitive position while generating data supporting broader commercial opportunities.

The convergence of federal validation, private capital, and manufacturing partnerships creates a pathway for Rocketvax to advance from preclinical promise toward commercial reality. Whether this combination delivers breakthrough products will depend on clinical trial outcomes generated over the coming years.